Table 1.
Baseline Characteristics and Clinical Manifestations
| Treatment Group | Linezolid-Containing | Non-Linezolid-Containing | P Value |
|---|---|---|---|
| No. | 20 (71) | 8 (29) | |
| Age at time of diagnosis, median (IQR) [range], y | 62 (52–68) [23–80] | 67 (56–74) [30–76] | .94 |
| Male sex | 15 (75) | 6 (75) | .99 |
| Urban residence (Darwin/Palmerston) | 13 (65) | 6 (75) | .99 |
| Indigenous ethnicity | 4 (20) | 2/7 (29) | .63 |
| Travel in last 6 mo | 1 (5) | 2 (25) | .18 |
| Hazardous alcohol | 3 (15) | 2 (25) | .60 |
| Diabetes mellitus | 6 (30) | 1 (13) | .63 |
| Chronic kidney disease | 3/15a (20) | 0 (0) | .52 |
| Hemodialysis | 1/15a (7) | 0 (0) | .99 |
| Cancer | 3 (15) | 3 (38) | .31 |
| Chronic lung disease | 12 (60) | 5 (63) | .99 |
| Smoker | 5 (25) | 5 (63) | .09 |
| Organ transplant | 1 (5) | 0 (0) | .99 |
| HIV-positive | 1 (5) | 0 (0) | .99 |
| Hemoglobin level, median (IQR), g/dL | 129 (109–139) | 120 (105–133) | .33 |
| Anemia (Hb < 100 g/dL) | 8 (40) | 2/6 (33) | .99 |
| Platelet count, median (IQR), ×103/μL | 282 (242–389) | 205 (131–245) | .07 |
| Thrombocytopenia (platelets < 150×103/μL) | 0 (0) | 2/6 (33) | .04 |
| Site/focus | |||
| Skin | 5 (25) | 1 (13) | .64 |
| Lung | 16 (80) | 7 (88) | .99 |
| Brain | 2 (10) | 0 (0) | - |
| Bones | 1 (5) | 0 (0) | - |
| Eyes (chorioretinitis) | 1 (5) | 0 (0) | .99 |
| Multiple foci present | 4 (20) | 0 (0) | .29 |
| Severe (ICU admission +/- multiple foci) | 6 (30) | 0 (0) | .14 |
| Immunosuppressed patientb | 5 (25) | 0 (0) | .28 |
Abbreviations: ICU, intensive care unit; IQR, interquartile range.
aValues are No. (%) unless otherwise specified.
bNo patient was on trimethoprim-sulfamethoxazole prophylaxis.